Video

Q&A With Anne Cross from Washington University School of Medicine: Additional Treatments Could Provide Benefit to Patients With Multiple Sclerosis

Author(s):

The development of new monoclonal antibodies could provide benefit for patients with multiple sclerosis in the future. Exactly how they will be used and what their usage could mean for treatment remains to be determined.

The development of new monoclonal antibodies could provide benefit for patients with multiple sclerosis in the future. Exactly how they will be used and what their usage could mean for treatment remains to be determined.

Anne H. Cross from the Washington University School of Medicine discussed this potential new treatment during the 2015 Annual Meeting of the Consortium of Multiple Sclerosis Centers in Indianapolis. Cross said that while these treatments have not been approved for patients with the relapsing form of the condition. She also added that if they are approved it will be important that only properly trained healthcare professionals provide them to patients.

Related Videos
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
Eric Lawitz, MD | Credit: UT Health San Antonio
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
A. Sidney Barritt, MD | Credit: UNC School of Medicine
© 2024 MJH Life Sciences

All rights reserved.